Advertisement

Psychopharmacology

, Volume 235, Issue 10, pp 2823–2829 | Cite as

Abuse liability of mitragynine assessed with a self-administration procedure in rats

  • Kai Yue
  • Theresa A. Kopajtic
  • Jonathan L. KatzEmail author
Original Investigation

Abstract

Rationale

Substantial use of the plant kratom for psychoactive effects has driven interest in its abuse liability. Several place conditioning studies suggest abuse liability of the active ingredient mitragynine, though studies of its self-administration have not been published.

Methods

Binding of mitragynine to rat brain mu, kappa, and delta opioid receptors was compared to that for heroin and morphine. Self-administration of mitragynine, heroin, methamphetamine, or saline was assessed during single-session substitutions in rats trained to self-administer methamphetamine (0.022 mg/kg/injection, i.v.) during 1-h daily sessions.

Results

Mitragynine had > 2- or ~ 16-fold greater affinity for the mu opioid receptor than, respectively, for kappa or delta opioid receptors. Its affinity for the mu receptor was ~ 200-fold less than that for morphine. In rats trained to self-administer methamphetamine, saline substitutions significantly decreased the number of responses, whereas different doses of methamphetamine (0.002–0.068 mg/kg/injection) or heroin (0.001–0.03 mg/kg/injection) maintained self-administration with maximal responding at 0.022 or 0.01 mg/kg/injection, respectively. In contrast, no dose of mitragynine maintained response rates greater than those obtained with saline. Presession mitragynine treatment (0.1 to 3.0 mg/kg) decreased response rates maintained by heroin but had little effect on responding maintained by methamphetamine across the same range of doses.

Conclusions

These results suggest a limited abuse liability of mitragynine and potential for mitragynine treatment to specifically reduce opioid abuse. With the current prevalence of opioid abuse and misuse, it appears currently that mitragynine is deserving of more extensive exploration for its development or that of an analog as a medical treatment for opioid abuse.

Keywords

Mitragynine Kratom Abuse liability Self-administration Methamphetamine Heroin Medical treatments Opioid abuse Rats 

Notes

Acknowledgments

We thank Drs. Christopher R. McCurdy for the initial advice on mitragynine and James H. Woods for the advice on the writing of this report.

Funding information

This project was funded by the National Natural Science Foundation of China (81302762) and the National Institute on Drug Abuse, Intramural Research Program. These studies were initiated at NIDA when Kai Yue was funded by a scholarship from the China Scholarship Council (CSC), a non-profit institution affiliated with the Ministry of Education of the P.R. China, Level 13, Building A3, No. 9 Chegongzhuang Avenue, Beijing 100044, P. R. China.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Bertalmio AJ, Woods JH (1989) Reinforcing effect of alfentanil is mediated by mu opioid receptors: apparent pA2 analysis. J Pharmacol Exp Ther 251:455–460PubMedGoogle Scholar
  2. Caggiula AR, Donny EC, Chaudhri N, Perkins KA, Evans-Martin FF, Sved AF (2002) Importance of nonpharmacological factors in nicotine self-administration. Physiol Behav 77:683–687CrossRefGoogle Scholar
  3. Cheaha D, Reakkamnuan C, Nukitram J, Chittrakarn S, Phukpattaranont P, Keawpradub N, Kumarnsit E (2017) Effects of alkaloid-rich extract from Mitragyna speciosa (Korth) Havil on naloxone-precipitated morphine withdrawal symptoms and local field potential in the nucleus accumbens of mice. J Ethnopharmacol 208:129–137CrossRefGoogle Scholar
  4. Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (KI) and the concentration which causes 50% inhibition of an enzymatic reaction. Biochem Pharmacol 22:403–411Google Scholar
  5. Dole VP, Nyswander M (1965) A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. JAMA 193: 646–650CrossRefGoogle Scholar
  6. Grundmann O (2017) Patterns of kratom use and health impact in the US — results from an online survey. Drug Alcohol Depend 176:63–70CrossRefGoogle Scholar
  7. Harrigan SE, Downs DA (1978) Continuous intravenous naltrexone effects on morphine selfadministration in rhesus monkeys. J Pharmacol Exp Ther 204: 481–486Google Scholar
  8. Harun N, Hassan Z, Navaratnam V, Mansor SM, Shoaib M (2015) Discriminative stimulus properties of mitragynine (kratom) in rats. Psychopharmacol 232:2227–2238CrossRefGoogle Scholar
  9. Hassan Z, Bosch OG, Singh D, Narayanan S, Kasinather BV, Seifritz E, Kornhuber J, Quednow BB, Müller CP (2017) Novel psychoactive substances — recent progress on neuropharmacological mechanisms of action for selected drugs. Front Psychiatry 8:152CrossRefGoogle Scholar
  10. Hemby SE, Mcintosh S, Cutler SJ, McCurdy CR (2018) Abuse liability of mitragynine and 7-hydroxymitragynine putative primary alkaloids of Mitragyna speciosa (kratom). Soc Neurosci Abstr 794:21Google Scholar
  11. Henningfield JE, Fant RV, Wang DW (2018) The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research. Psychopharmacol 235:573–589CrossRefGoogle Scholar
  12. Himmelsbach CK (1941) The effects of certain chemical changes on the addiction characteristics of drugs of the morphine, codeine series. J Pharmacol Exp Ther 71:41–48Google Scholar
  13. Hiranita T, Kohut SJ, Soto PL, Tanda G, Kopajtic TA, Katz JL (2014) Preclinical efficacy of N-substituted benztropine analogs as antagonists of methamphetamine self-administration in rats. J Pharmacol Exp Ther 348:174–191CrossRefGoogle Scholar
  14. Inturrisi CE, Schultz M, Shin S, Umans JG, Angel L, Simon EJ (1983) Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci 33(Suppl 1):773–776CrossRefGoogle Scholar
  15. Kai Y, Ma B, Chen L, Tian X, Ru Q, Gan Y, Wang D, Jin G, Li C (2014) l-Stepholidine, a naturally occurring dopamine D1 receptor agonist and D2 receptor antagonist, attenuates heroin self-administration and cue-induced reinstatement in rats. Neuroreport 25:7–11Google Scholar
  16. Kohut SJ, Bergman J (2016) Reinforcing effectiveness of nicotine in nonhuman primates: effects of nicotine dose and history of nicotine self-administration. Psychopharmacol 233:2451–2458CrossRefGoogle Scholar
  17. Kong WM, Mohamed Z, Alshawsh MA, Chik Z (2017) Evaluation of pharmacokinetics and blood-brain barrier permeability of mitragynine using in vivo microdialysis technique. J Pharm Biomed Anal 143:43–47CrossRefGoogle Scholar
  18. Kruegel AC, Grundmann O (2018) The medicinal chemistry and neuropharmacology of kratom: a preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacol 134:108–120CrossRefGoogle Scholar
  19. Kruegel AC, Gassaway MM, Kapoor A, Váradi A, Majumdar S, Filizola M, Javitch JA, Sames D (2016) Synthetic and receptor signaling explorations of the Mitragyna alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators. J Am Chem Soc 138:6754–6764CrossRefGoogle Scholar
  20. Mechner F, Latranyi M (1963) Behavioral effects of caffeine, methamphetamine, and methylphenidate in the rat. J Exp Anal Behav 6:331–342CrossRefGoogle Scholar
  21. Oldendorf WH, Hyman S, Braun L, Oldendorf SZ (1972) Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science 178:984–986CrossRefGoogle Scholar
  22. Smith KE, Lawson T (2017) Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program. Drug Alcohol Depend 180:340–348CrossRefGoogle Scholar
  23. Sufka KJ, Loria MJ, Lewellyn K, Zjawiony JK, Ali Z, Abe N, Khan IA (2014) The effect of Salvia divinorum and Mitragyna speciosa extracts, fraction and major constituents on place aversion and place preference in rats. J Ethnopharmacol 151:361–364CrossRefGoogle Scholar
  24. Swogger MT, Walsh Z (2018) Kratom use and mental health: a systematic review. Drug Alcohol Depend 183:134–140CrossRefGoogle Scholar
  25. Takayama H (2004) Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chem Pharm Bull (Tokyo) 52:916–928CrossRefGoogle Scholar
  26. US Drug Enforcement Administration (2016) Schedules of controlled substances: placement of mitragynine and 7-Hydroxymitragynine into schedule I. Federal Register. https://www.federalregister.gov/documents/2016/08/31/2016-20803/schedules-of-controlledsubstances-temporary-placement-of-mitragynine-and-7-hydroxymitragynine-into. Accessed 10 April 2017
  27. Váradi A, Marrone GF, Palmer TC, Narayan A, Szabó MR, Le Rouzic V, Grinnell SG, Subrath JJ, Warner E, Kalra S, Hunkele A (2016) Mitragynine/Corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit β-Arrestin-2. J Med Chem 59:8381–8397CrossRefGoogle Scholar
  28. Vicknasingam B, Narayanan S, Beng GT, Mansor SM (2010) The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy. Int J Drug Policy 21:283–288CrossRefGoogle Scholar
  29. Way EL, Kemp JW, Young JM, Grassetti DR (1960) The pharmacologic effects of heroin in relationship to its rate of biotransformation. J Pharmacol Exp Ther 129:144–154PubMedGoogle Scholar
  30. Way EL, Young JM, Kemp JW (1965) Metabolism of heroin and its pharmacologic implications. Bull Narc 17:25–33Google Scholar
  31. Winger G, Skjoldager P, Woods JH (1992) Effects of buprenorphine and other opioid agonists and antagonists on alfentanil- and cocaine-reinforced responding in rhesus monkeys. J Pharmacol Exp Ther 261:311–317PubMedGoogle Scholar
  32. Young AM, Woods JH (1981) Maintenance of behavior by ketamine and related compounds in rhesus monkeys with different self-administration histories. J Pharmacol Exp Ther 218:720–727PubMedGoogle Scholar
  33. Yusoff NHM, Suhaimi FW, Vadivelu RK, Hassan Z, Rümler A, Rotter A, Amato D, Dringenberg HC, Mansor SM, Navaratnam V, Müller CP (2016) Abuse potential and adverse cognitive effects of mitragynine (kratom). Addict Biol 21:98–110CrossRefGoogle Scholar
  34. Yusoff NHM, Mansor SM, Müller CP, Hassan Z (2017) Opioid receptors mediate the acquisition, but not the expression of mitragynine-induced conditioned place preference in rats. Behav Brain Res 332:1–6CrossRefGoogle Scholar
  35. Yusoff NHM, Mansor SM, Müller CP, Hassan Z (2018) Baclofen blocks the acquisition and expression of mitragynine-induced conditioned place preference in rats. Behav Brain Res 345:65–71CrossRefGoogle Scholar
  36. Zanettini C, Wilkinson DS, Katz JL (2018) Behavioral economic analysis of the effects of N-substituted benztropine analogs on cocaine self-administration in rats. Psychopharmacol 235: 47–58CrossRefGoogle Scholar
  37. Zhang F (2006) SuperState: a computer program for the control of operant behavioral experimentation. J Neurosci Methods 155:194–201CrossRefGoogle Scholar

Copyright information

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2018

Authors and Affiliations

  • Kai Yue
    • 1
  • Theresa A. Kopajtic
    • 2
  • Jonathan L. Katz
    • 2
    Email author
  1. 1.Wuhan Institute of Biomedical ScienceJianghan UniversityWuhanChina
  2. 2.Psychobiology Section, Molecular Neuropsychiatry Research Branch, Intramural Research ProgramNational Institute on Drug Abuse, National Institutes of Health, Department of Health and Human ServicesBaltimoreUSA

Personalised recommendations